Abstract: This invention relates to the engineering of animal cells, preferably mammalian, more preferably rat, that are deficient due to the disruption of tumor suppressor gene(s) or gene product(s). In another aspect, the invention relates to genetically modified rats, as well as the descendants and ancestors of such animals, which are animal models of human cancer and methods of their use.
Type:
Grant
Filed:
June 1, 2021
Date of Patent:
April 15, 2025
Assignee:
Hera Testing Laboratories, Inc.
Inventors:
Eric M. Ostertag, John Stuart Crawford, Joseph Ruiz
Abstract: This invention relates to the engineering of animal cells, preferably mammalian, more preferably rat, that are deficient due to the disruption of tumor suppressor gene(s) or gene product(s). In another aspect, the invention relates to genetically modified rats, as well as the descendants and ancestors of such animals, which are animal models of human cancer and methods of their use.
Type:
Grant
Filed:
December 16, 2021
Date of Patent:
December 26, 2023
Assignee:
Hera Testing Laboratories, Inc.
Inventors:
Eric M. Ostertag, John Stuart Crawford, Joseph Ruiz
Abstract: This invention relates to the engineering of animal cells, preferably mammalian, more preferably rat, that are deficient due to the disruption of tumor suppressor gene(s) or gene product(s). In another aspect, the invention relates to genetically modified rats, as well as the descendants and ancestors of such animals, which are animal models of human cancer and methods of their use.
Type:
Grant
Filed:
November 13, 2017
Date of Patent:
August 17, 2021
Assignee:
Hera Testing Laboratories, Inc.
Inventors:
Eric M. Ostertag, John Stuart Crawford, Joseph Ruiz
© 2026 Justia
